Key result
Digoxin administration was not associated with an increased risk of all-cause mortality in AF patients with heart failure or without heart failure.
Why the study?
Digoxin is widely used in AF and HF, but current evidence regarding its association with clinical outcomes remains conflicting.
Does digoxin therapy improve all-cause mortality in patients with atrial fibrillation with or without heart failure?
Cohort (n=698)
Does digoxin therapy improve all-cause mortality in patients with atrial fibrillation with or without heart failure?
In a contemporary cohort of patients with atrial fibrillation, digoxin use was not associated with an increased risk of mortality or hospitalization, regardless of concomitant heart failure.
Answers are grounded in this paper and cite their sources.
Neutral mortality signal with digoxin in this retrospective cohort; leaves open its role pending prospective trials.
BACKGROUND: Digoxin is widely used in atrial fibrillation (AF) and heart failure (HF). However, current evidence regarding its association with clinical outcomes is conflicting. AIM: To investigate the relationship between digoxin therapy and adverse outcomes in patients with AF, with or without HF, in a contemporary AF cohort. METHODS: We performed a retrospective analysis of data from 698 patients, who were followed over a median of 2.5 years. The primary outcome was all-cause mortality and the secondary outcome was all-cause hospitalization, in a time-to-event analysis. Propensity scores were used to derive matched populations, balanced on key baseline covariates. To limit potential confounding, inverse probability of treatment weighting (IPTW) analysis was performed. RESULTS: Among patients with HF, 39 (10.5%) were administered digoxin at baseline, whereas 331 (89.5%) were not. Digoxin administration was not associated with an increased risk of death (hazard ratio (HR) in the digoxin group, 1.21; 95% Confidence Interval (CI), 0.69 to 2.13, p = 0.50) or hospitalization of any cause (HR 1.15; 95% CI, 0.67 to 1.96; p = 0.60). Among patients without HF, 11 (3.5%) were administered digoxin, with neutral effects on all-cause mortality (HR: 3.25; 95% CI, 0.98 to 10.70), p = 0.06) and all-cause hospitalization (HR, 1.15; 95% CI, 0.67 to 1.96, p = 0.60). Qualitatively, consistent results were observed using IPTW. CONCLUSIONS: Among patients with AF, digoxin administration was not associated with an increased risk of death and hospitalization for any cause, irrespective of HF status.
No takes yet. Share an insight, caveat, or question.
Botis et al. (2022) conducted a cohort in Atrial fibrillation with or without heart failure (n=698). Digoxin vs. No digoxin was evaluated on all-cause mortality (HR 1.21, 95% CI 0.69-2.13, p=0.50). Digoxin administration was not associated with an increased risk of all-cause mortality in AF patients with heart failure or without heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: